Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CXCR3
REST API REST API
Homo sapiens
CXCR3 is differentially expressed in 212 experiments: 95 organism parts: kidney, amygdala, ... (93 more);, 178 disease states: normal, control, ... (176 more);, 77 cell types 198 cell lines 20 compound treatments and 61 other conditions.
Synonyms GPR9, CD183, MigR, CMKAR3, CKR-L2, IP10-R
Orthologs cxcr3.1 (Danio rerio)   CXCR3_BOVIN (Bos taurus)   Cxcr3 (Mus musculus)   Cxcr3 (Rattus norvegicus)   cxcr3 (Xenopus laevis)   CXCR3_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, elevation of cytosolic calcium ion concentration, cytoplasm, G-protein coupled receptor activity, cellular component movement, G-protein coupled receptor protein signaling pathway, signal transducer activity, external side of plasma membrane, cell adhesion, integral to plasma membrane, receptor activity, chemotaxis, integral to membrane, calcium-mediated signaling, chemokine binding, C-X-C chemokine receptor activity, chemokine receptor activity
InterPro Term GPCR_Rhodpsn_supfam, ATII_rcpt, 7TM_GPCR_Rhodpsn, Chemokine_rcpt, Chemokine_CXCR4, Chemokine_CXCR3
UniProt Accession C9JB00, P49682
Search EB-eye ENSG00000186810
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-GEOD-1577, ... (24 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-22639, E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, ... (22 experiments)

Factor Value U/D Experiments
PC3
2
E-GEOD-5258, E-MEXP-2034
CCRFCEM
2
E-GEOD-24147, E-MTAB-37
MCF-7
2
E-GEOD-5823, E-GEOD-19639
HL-60
1
2
E-GEOD-24147, E-GEOD-5258, E-MTAB-37
C3A
1
E-MTAB-37
BC-5
1
E-GEOD-2149
192 more value(s).


Cell type

studied in E-GEOD-22529, E-TABM-40, E-GEOD-22373, E-GEOD-3920, E-MEXP-66, ... (41 experiments)

Factor Value U/D Experiments
testis - germ cell
2
E-AFMX-5, E-TABM-145
2
2
E-TABM-145, E-TABM-130
CD8+ T cell
2
E-GEOD-6740, E-GEOD-19069
adult native RPE from 78 y.o. donor
1
E-GEOD-18811
primary CD34- mesenchymal stem cell
1
E-MEXP-66
purified B cells from peripheral blood from donors 60 years of age and older
1
E-GEOD-22529
71 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-22529, E-GEOD-15960, E-GEOD-1869, ... (45 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-GEOD-6691, E-MTAB-37
lung adenocarcinoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
control
1
2
E-GEOD-16363, E-GEOD-8121, E-GEOD-21912
colorectal carcinoma
1
E-GEOD-4045
cancerous
1
E-TABM-15
172 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-6907, E-TABM-782, E-GEOD-5824, E-GEOD-5099, ... (13 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-5824, E-GEOD-412, E-TABM-782, E-MEXP-1958, E-GEOD-7400 ... (5 experiments)
potassium dichromate
1
E-GEOD-6907
actinomycin D
2
1
E-GEOD-6400
glutamine
1
E-MEXP-1335
control
31
1
E-GEOD-3284
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
14 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
47
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-20499, ... (9 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-3140, E-MEXP-958, E-MTAB-62

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-577, E-GEOD-21138, E-GEOD-19665 ... (5 experiments)

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-17385

Genotype
studied in E-GEOD-17476, E-TABM-601

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20540, E-GEOD-22278, E-MEXP-2146 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-3720, E-GEOD-1926, E-MEXP-2069, ... (28 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-GEOD-9723, E-MEXP-561

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1657 ... (5 experiments)

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Replicate
studied in E-GEOD-15811

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-13818, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4922

Tumor size
studied in E-GEOD-3494

Processing time: 0.595 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM